Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Phase 3Iopofosine I 131Positive

AI Analysis

Summary

Cellectar Biosciences initiated site activation for a confirmatory Phase 3 study of Iopofosine I 131, with New Drug Application submission planned for mid-2027 under FDA's Accelerated Approval Program.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Site activation initiated for confirmatory Phase 3 study

Importance:6/10

Sentiment:

0.60

Phase 3Accelerated ApprovalNDA submission plannedIopofosine I 131

Related Companies

$CLRB

Read the original article

Published by GlobeNewswire Pharma on August 13, 2026 11:15 AM

Read Original